Pro Traders Forum

[TradeForProfits]

$PBIO water soluble #CBD platform expansion, larger market reach:

https://finance.yahoo.com/news/pressure-biosciences-accelerating-rollout-proprietary-131500938.html

Pressure BioSciences Accelerating Rollout of Proprietary UST Platform for Water-Soluble CBD with Planned Release of Additional BaroShear Instrument
PR Newswire PR NewswireJanuary 30, 2020
Introduction of New Benchtop, R&D Scale, UST-Based "BaroShear Mini" in Q3 2020 Expected to Speed Market Penetration of PBI's UST Platform for Processing CBD and Other Oils into Stable, High Quality, Water-Soluble Nanoemulsions

New Instrument for Product Formulation and Development to Address Many Large and Diverse Markets

SOUTH EASTON, Mass., Jan. 30, 2020 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences and other industries, today announced that the Company plans to release a benchtop, R&D scale, Ultra Shear Technology™ ("UST™")-based BaroShear instrument to the market in the third quarter of 2020. The Company believes this new instrument will address a significant un-met need in product formulation and development laboratories in the cannabis, cosmetics, nutraceuticals, pharmaceuticals, and other large and diverse markets for processing CBD and other oils into stable, effectively water-soluble, highly absorbable nanoemulsions of oil in water.

CBD and other cannabinoids are extracted from the hemp plant in an oil form. The water-based biology of human bodies has difficulty accessing and absorbing oily molecules from the surface of ingested or topically applied hemp oil droplets. The ultra-low droplet sizes created by UST in nanoemulsions are designed to deliver levels of bioavailability and effectiveness that far exceed the dosing efficiencies achieved from today's macro or microemulsions of CBD Oil.

Kenneth F. Micciche, Director of PBI's UST Program, said: "We are very excited about the planned release later this year of the third instrument in the BaroShear product family. The aggressive marketing campaign we have underway for the pre-sale of our BaroShear K45 system and for the 2021 release of our industrial-scale BaroShear Max instrument has been well received by manufacturing laboratories. However, it has become apparent that product research and development labs prefer a smaller, bench-top, lower price-point, minimal throughput UST-based instrument. The BaroShear Mini clearly answers that need and will do so without cannibalizing sales to larger manufacturing facilities. We believe this new instrument will add significantly to PBI's revenue in 2020."

Richard T. Schumacher, President and CEO of PBI commented: "It has become apparent that Pressure BioSciences' breakthrough UST platform is a potential market-changing technology enabling a new generation of CBD and other cannabinoid products to more effectively meet consumer and supplier objectives. By delivering effective water solubility of cannabinoids, PBI's UST offers the promise of high absorption rates and bioavailability from ingestion or topical application of cannabinoid products. Most importantly, this delivers new confidence in controlled, safe and effective dosing for consumers. It also offers substantial cost reductions achieved as suppliers can eliminate the overloading of CBD and other cannabinoids into products, previously required to achieve targeted dosing levels."

Jeffrey N. Peterson, PBI Board Chairman, said: "Our innovation of the UST platform offers the potential to allow a universe of valuable materials that exist as oils (and thus do not naturally mix with water) to be delivered in effectively water-soluble preparations that can be easily absorbed by the water-based biology of humans and other animals, or applied in industrial and consumer applications, without requiring heavy use of undesirable chemical additives."

Mr. Peterson continued: "We believe that PBI will transform a vast range of applications with UST, that extend across multiple very large markets from dairy and other foods/beverages, to pharmaceuticals, nutraceuticals, and industrial applications. This is the technology platform that we believe will propel PBI into multi-billion dollar market opportunities, with resulting market value realization for our shareholders."

About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the "BaroFold" technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology ("UST") platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.